Pfizer Inc. And BioNTech SE said that the third dose of their COVID-19 vaccine neutralized the Omicron variant in laboratory tests, but the two-dose regimen was significantly less effective in stopping the virus.
The companies said the third dose increased antibodies by 25-fold compared to the two doses in the Omron version. Still, two doses can prove to be effective in preventing serious illness from Kovid-19, he said.
Pfizer and BioNTech are working on an Omicron-specific vaccine, which is expected to be available by March.
The companies’ initial findings come a day after scientists in South Africa reported the findings of preliminary laboratory tests, in which the Pfizer-BioNtech vaccine produced one-forty-fifth of the infection-fighting antibodies against Omicron compared to the original version of the virus. has generated.
Omicron was first identified by scientists in South Africa last month. The World Health Organization has since considered it “a form of anxiety” and has since been found around the world, including in the US.
Researchers are trying to understand how contagious the new strain is, how well it may be able to survive COVID-19 vaccines and whether it causes severe disease. Some preliminary reports suggest that the variant is more contagious but may cause milder illness, although researchers say it is too early to know.
This story has been published without modification in text from a wire agency feed
Never miss a story! Stay connected and informed with Mint.
download
Our App Now!!
,